The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).
 
Teresa Macarulla
Consulting or Advisory Role - AstraZeneca; Baxalta; Baxter; Celgene; Eisai; Genzyme; Incyte; Ipsen; Lilly; Menarini; MSD; Polaris; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Shire; Surface Oncology
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Merck; Sanofi; SERVIER
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Li-Tzong Chen
Leadership - ScinoPharm
Honoraria - OBI Pharma; PharmaEngine; Taivex Therapeutics
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CStone Pharmaceuticals; Ipsen; Lilly; MSD; Novartis; Ono Pharmaceutical; SynCoreBio; TTY Biopharm
Research Funding - ACT Genomics (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); SynCoreBio (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - HuniLife ENO-1 Ab
 
Michael B. Sawyer
Stock and Other Ownership Interests - AstraZeneca; Gilead Sciences
Honoraria - Baxter; Bristol-Myers Squibb; Celgene; Fresenius Kabi; Ipsen; ipsen; LEO Pharma; Merck; Mylan; Novartis; Novartis Canada Pharmaceuticals Inc; nutricia; pfizer; Sanofi; Shire; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Celgene; Immuneering; Ipsen; Ipsen; LEO Pharma; Merck; Nutricia; Pfizer; Yinuoke
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Lilly (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - My lab discovered that all the competitive tyrosine kinase inhibitors such as sunitinib and gefitinib have additional pharmacological properties. This additional pharmacologic property causes intestinal epithelial cells to active their chloride channels l
Travel, Accommodations, Expenses - Amgen; Ipsen; LEO Pharma; Novartis Canada Pharmaceuticals Inc; Nutricia; pfizer
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; Exelixis; Genentech; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Andres J. Muñoz Martín
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Pfizer; Celgene; Daiichi Sankyo; Incyte; LEO Pharma; Lilly; MSD Oncology; Roche; Sanofi
Speakers' Bureau - Rovi
Research Funding - LEO Pharma; Sanofi
Patents, Royalties, Other Intellectual Property - Risk assessment model in venous thromboembolism in cancer patients
Travel, Accommodations, Expenses - Amgen; Celgene; Merck Serono; Roche
 
Yang Sheng-Shun
Consulting or Advisory Role - Abbvie; Gilead Sciences; Ipsen; Roche
Speakers' Bureau - Abbvie; Gilead Sciences; MBS; MSD
 
Samuel Le Sourd
No Relationships to Disclose
 
John Morris
Speakers' Bureau - Merck
Patents, Royalties, Other Intellectual Property - NIH/NCI
 
Michael Fuchs
Speakers' Bureau - Chronic Liver Disease Foundation; Simply Speaking PAH
Research Funding - Bristol-Myers Squibb; Gilead Sciences; H3 Biomedicine; Intercept Pharmaceuticals; Novartis
 
Thomas Benjamin Karasic
Honoraria - Exelixis; Incyte; Pfizer
Research Funding - Bristol-Myers Squibb; Celgene; H3 Biomedicine; Lilly; Sirtex Medical; Syndax; Taiho Pharmaceutical; Tempest Therapeutics
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
Wei-Peng Yong
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Eisai; Ipsen; Novartis
Speakers' Bureau - AstraZeneca; Bayer; MSD; Sanofi
Patents, Royalties, Other Intellectual Property - MiRXES
 
Anand Selvaraj
Employment - H3 Biomedicine
Leadership - H3 Biomedicine
Stock and Other Ownership Interests - Moderna Therapeutics
Patents, Royalties, Other Intellectual Property - Own patents through work at H3 Biomedicine
Travel, Accommodations, Expenses - H3 Biomedicine
 
Benoit Destenaves
Employment - AstraZeneca; H3 Biomedicine
Stock and Other Ownership Interests - AstraZeneca
 
Jianjun Alan Xiao
Employment - H3 Biomedicine; Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - H3 Biomedicine
 
Ronald Gomez
No Relationships to Disclose
 
Antonio Gualberto
Employment - H3 Biomedicine; H3 Biomedicine; Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
Patents, Royalties, Other Intellectual Property - Patent of HRAS mutation as biomarker for farnesyl transferase inhibitor treatment in HNSCC
Travel, Accommodations, Expenses - Kura Oncology
 
J. Marc Marc Pipas
Employment - H3 Biomedicine; Merrimack
Leadership - PanTher Therapeutics
Stock and Other Ownership Interests - Merrimack
Consulting or Advisory Role - PanTher Therapeutics; PanTher Therapeutics
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer